Aethlon Medical (OTC:AEMD) said it dealt $3.3 million worth of securities an investment fund, as it pursues various approvals for its Hemopurifier blood filtration device.
“The proceeds will be directed toward funding a clinical study, general working purposes and debt reduction,” CEO James Joyce told MassDevice.com via email, noting that the backer is a healthcare-focused investment fund.
Aethlon grabbed headlines this fall when the Hemopurifier was used to help successfully treat a critically ill Ebola patient in Germany.
Joyce told MassDevice.com last month that the company hoped to begin a U.S. clinical trial for treating hepatitis C by the end of the year, and to eventually expand testing to include deadly pathogens such as Ebola.
San Diego-based Aethlon registered for a $2 million funding round back in November 2013.
